RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells.
PURPOSE: Phase I trial to study the effectiveness of interleukin-2 following bone marrow
transplantation in treating patients who have hematologic cancer at risk of relapse.
OBJECTIVES: I. Determine the toxicity and maximum tolerated dose of interleukin-2 following
allogeneic T-cell depleted bone marrow transplant in patients with hematologic malignancies
at high risk of relapse. II. Determine the optimal dose of interleukin-2 in this regimen
which will result in maximal natural killer cell and lymphokine activated killer cell
activity in vitro.
OUTLINE: This is a dose escalation study. Patients receive CD34+ stem cell augmented donor
bone marrow on day 0 on another protocol. Patients then receive interleukin-2 (IL-2)
subcutaneously on day 30. Treatment continues for 12 weeks in the absence of dose limiting
toxicity. Cohorts of 4 patients receive escalating doses of IL-2 until the maximum tolerated
dose (MTD) is determined. The MTD is defined as the dose prior to that which causes at least
grade 3 toxicity.
PROJECTED ACCRUAL: A total of 18-24 patients will be accrued for this study within 12-18
DISEASE CHARACTERISTICS: Any of the following diagnoses eligible: Acute myelogenous
leukemia beyond first complete remission Acute lymphoblastic leukemia Chemotherapy
resistant non-Hodgkin's lymphoma Chemotherapy resistant Hodgkin's disease Multiple myeloma
Primary refractory acute leukemia Secondary leukemia Chronic myelomonocytic leukemia No
chronic myelogenous leukemia, aplastic anemia, or myelofibrosis HLA identical related
PATIENT CHARACTERISTICS: Age: 0.5 to 65 Performance status: ECOG 0-2 Life expectancy: Not
specified Hematopoietic: See Disease Characterisitics Hepatic: Bilirubin less than 2.5
mg/dL (unless Gilbert's syndrome present) Renal: Creatinine no greater than 2 mg/dL
Cardiovascular: No active congestive heart failure, arrhythmia, or angina pectoris No
myocardial infarction within past 12 months Pulmonary: No requirement for oxygen Other:
Afebrile for greater than 48 hours No active, serious infection (e.g., sepsis,
mucormycosis, or uncontrolled aspergillosis) No debilitating medical or psychiatric
illness that would preclude compliance Not pregnant Fertile patients must use effective
PRIOR CONCURRENT THERAPY: Biologic therapy: No prior bone marrow transplant Chemotherapy:
See Disease Characteristics Endocrine therapy: No concurrent corticosteroids Radiotherapy:
Not specified Surgery: Not specified